Ozempic maker Novo Nordisk to cut 9,000 jobs amid increased competition | Pharmaceuticals industry

Wegovy and Ozempic Wegovy and Ozempic’s weight loss and Danish producer of diabetes drugs, reducing a snow warning in the midst of a violent competition from US rival Eli Lilly.

Novo Nordisk’s decision to reduce 11% of the 78,400 global labor force, Wegovy’s sales slowed down sharply because Eli Lilly lost its ground to Mounjaro jabs, and the pharmacy industry is faced with the targeted threat.

In recent years, GLP-1 diabetes and obesity drugs developed sales of the most valuable company in Europe Danish drug producer, 5,000 business cuts will be in their own country, he said.

Novo Nordisk’s market value fell approximately 100 billion dollars after the previous snow warning in early August. Studies have shown that Eli Lilly’s Mounjaro is more effective in weight reduction than Wegovy. Both can be prescribed by NHS doctors to patients with high clinical need. Novo Nordisk’s Özempic injection is also available in NHS as Type 2 diabetes treatment.

Novo Nordisk estimates that business cuts will save 8 billion crowns (£ 930 million) annually by 2026.

However, they will cost 8 billion chronices in one-time restructuring fees and will ask Novo Nordisk to reduce the activity profit growth forecast for this year from 10-16%to 4-10%.

They are Mike Dustdar’s first big move, A Austrian-American-American Businessman Lars Fruergaard Jørgensen, who has been leading the company since 2017 as CEO last month and pointed to potential layoffs last month.

“It is always difficult to see that your talented and valuable colleagues are gone, but we are convinced that this is the right thing for Novo Nordisk’s long -term success,” Dustdar said. “We need a change in our mindset and approach so that we can be faster and more agile.”

Novo Nordisk, the new obesity drug Cagrisema’s disappointing results were also hit. Eli could not perform better than Mounjaro than Lilly Late weight loss in a clinical study.

Sales also hit the “compound ği in the US, where pharmacies, which were permitted during drug scarcity but have recently been officially terminated by the US regulator, formed weight loss drugs.

Jørgensen said last month, the general, the imitator market was “equal to our business ve and that the compound versions of Wegovy were sold at a much lower price point”.

Together with other European pharmaceutical companies, Novo Nordisk faces repeated threats to implement sector -specific tariffs for imports from drug producers who do not carry some of Donald Trump’s production to the USA.

Susannah Streeter, a Hargreaves Lansdown analyst, said: “Novo Nordisk, who grows fat in the spoils of weight loss drugs, feels the effects of competitors entering the field. The uncertainty on American tariffs has been a risk that continues to overshadow the sector.

In the last five years, Novo Nordisk has increased the number of employees by 75%as his performance increased due to the global popularity of weight loss drugs that need to be injected once a week.